Breakout Setups
ROIV appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
ROIVANT SCIENCES LTD (ROIV) Stock Price & Overview
NASDAQ:ROIV • BMG762791017
Current stock price
29.11 USD
-0.01 (-0.03%)
Last:
The current stock price of ROIV is 29.11 USD. Today ROIV is down by -0.03%. In the past month the price increased by 2.97%. In the past year, price increased by 186.9%.
ROIV Key Statistics
52-Week Range10.01 - 30.33
Current ROIV stock price positioned within its 52-week range.
1-Month Range25.9508 - 29.69
Current ROIV stock price positioned within its 1-month range.
- Market Cap
- 20.834B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.17
- Dividend Yield
- N/A
ROIV Stock Performance
Today
-0.03%
1 Week
+4.94%
1 Month
+2.97%
3 Months
+25.90%
Longer-term
6 Months +68.71%
1 Year +186.90%
2 Years +167.16%
3 Years +240.59%
5 Years N/A
10 Years N/A
ROIV Stock Chart
ROIV Stock Screens
ROIV currently appears in the following ChartMill screener lists.
ROIV Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ROIV. When comparing the yearly performance of all stocks, ROIV is one of the better performing stocks in the market, outperforming 96.05% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ROIV Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ROIV. ROIV has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ROIV Earnings
On February 6, 2026 ROIV reported an EPS of -0.38 and a revenue of 2.00M. The company missed EPS expectations (-17.28% surprise) and missed revenue expectations (-69.72% surprise).
Next Earnings DateN/A
Last Earnings DateFeb 6, 2026
PeriodQ3 / 2026
EPS Reported-$0.38
Revenue Reported1.999M
EPS Surprise -17.28%
Revenue Surprise -69.72%
ROIV Forecast & Estimates
19 analysts have analysed ROIV and the average price target is 33.29 USD. This implies a price increase of 14.36% is expected in the next year compared to the current price of 29.11.
For the next year, analysts expect an EPS growth of -418.84% and a revenue growth -88.35% for ROIV
Analysts
Analysts86.32
Price Target33.29 (14.36%)
EPS Next Y-418.84%
Revenue Next Year-88.35%
ROIV Groups
Sector & Classification
ROIV Financial Highlights
Over the last trailing twelve months ROIV reported a non-GAAP Earnings per Share(EPS) of -1.17. The EPS decreased by -680% compared to the year before.
Income Statements
Revenue(TTM)13.31M
Net Income(TTM)-809.24M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.49% | ||
| ROE | -18.96% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-265.22%
Sales Q2Q%-84.03%
EPS 1Y (TTM)-680%
Revenue 1Y (TTM)-73.6%
ROIV Ownership
Ownership
Inst Owners67.97%
Shares715.70M
Float517.86M
Ins Owners3.76%
Short Float %4.81%
Short Ratio3.96
ROIV Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.96 | 371.899B | ||
| AMGN | AMGEN INC | 15.21 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.7 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.93 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.16 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.08 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.87 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.66 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ROIV
Company Profile
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Company Info
IPO: 2020-12-03
ROIVANT SCIENCES LTD
7Th Floor, 50 Broadway
London GB
Employees: 750
Phone: 4412955950
ROIVANT SCIENCES LTD / ROIV FAQ
What does ROIVANT SCIENCES LTD do?
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Can you provide the latest stock price for ROIVANT SCIENCES LTD?
The current stock price of ROIV is 29.11 USD. The price decreased by -0.03% in the last trading session.
What is the dividend status of ROIVANT SCIENCES LTD?
ROIV does not pay a dividend.
What is the ChartMill rating of ROIVANT SCIENCES LTD stock?
ROIV has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of ROIVANT SCIENCES LTD (ROIV)?
ROIVANT SCIENCES LTD (ROIV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.17).
Would investing in ROIVANT SCIENCES LTD be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ROIV.